Ex vivo effect of varespladib on secretory phospholipase A2 alveolar activity in infants with ARDS - Wikidata - wikimedia - TriplyDB

Ex vivo effect of varespladib on secretory phospholipase A2 alveolar activity in infants with ARDS

Ex vivo effect of varespladib on secretory phospholipase A2 alveolar activity in infants with ARDS

http://www.wikidata.org/entity/Q34447842

about

Lack of group X secreted phospholipase A₂ increases survival following pandemic H1N1 influenza infection.Discontinued drugs for pulmonary, allergy, gastrointestinal, arthritis (2012).

P2860

Q30361318-71EDE355-8925-4C67-B203-1C4287738E91 Q38136273-6ABA0D64-F71F-401D-9CF2-65C704E89F1F

P2860

Ex vivo effect of varespladib on secretory phospholipase A2 alveolar activity in infants with ARDS

http://www.wikidata.org/entity/Q34447842

description

2012 nî lūn-bûn

@nan

2012 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Ex vivo effect of varespladib ...... activity in infants with ARDS

@ast

Ex vivo effect of varespladib ...... activity in infants with ARDS

@en

Ex vivo effect of varespladib ...... activity in infants with ARDS

@nl

type

label

Ex vivo effect of varespladib ...... activity in infants with ARDS

@ast

Ex vivo effect of varespladib ...... activity in infants with ARDS

@en

Ex vivo effect of varespladib ...... activity in infants with ARDS

@nl

prefLabel

Ex vivo effect of varespladib ...... activity in infants with ARDS

@ast

Ex vivo effect of varespladib ...... activity in infants with ARDS

@en

Ex vivo effect of varespladib ...... activity in infants with ARDS

@nl

P1433

Q34447842-367F3E01-8172-44C0-82DA-F2C902B04F31

P1476

Q34447842-DD4DEC89-AE8E-43C3-B24F-51319FD9C26D

P2093

Q34447842-0A67777F-3332-45FB-A43A-5CFD79AD31B5

Q34447842-1FCEE55C-EA44-4301-A2B6-2221F878BB6E

Q34447842-3F9AC837-30EB-43EF-8715-BE9BFD8BA1AC

Q34447842-513CAB9E-5DCE-43B7-858A-CCC66E7B467A

Q34447842-7E29AEB6-0689-4804-AB74-0F5884D77E7B

Q34447842-B686BF10-BE9F-40B5-A11B-E57352002874

Q34447842-BBDFA87D-3B69-46E6-B1AD-2DB6DBCE2159

Q34447842-DC23CA32-E33B-4BD6-BFC7-44CB4A3D629B

P2860

Q34447842-11E2B12E-793B-43F6-92B5-A155B1DB8230

Q34447842-131672A0-B69B-4C13-A000-A95FFDCE582A

Q34447842-1F755EB1-5CDC-4554-9288-EBBDD921450C

Q34447842-330D724C-361E-498A-B985-EB29D7B5C950

Q34447842-430AFE67-ED21-480E-B1A3-C020411D47FB

Q34447842-4B5F810B-F781-446C-9797-00D0A8EA2CEF

Q34447842-52B38CCD-E40F-439E-8954-430C899D38FC

Q34447842-5629C3BD-14D7-468E-8E42-2CBC00B39A2D

Q34447842-5A84BFA0-D817-4775-A40E-BB2E5532D3DD

Q34447842-5B6B40FA-1414-41F5-83A7-9E61AD2F6CC7

P304

Q34447842-E86391D1-8B3D-42D1-9896-2A1AEF794652

P31

Q34447842-AD0CEE39-B8D9-4494-B924-F99A16C0A593

P356

Q34447842-D6633CD1-B48F-4D68-97A3-FD9FDD33210B

P407

Q34447842-5BA39871-FC0C-41C2-8FF9-DF157240F583

P433

Q34447842-051DA67D-925F-46C3-9522-3FBF846C7A32

P478

Q34447842-4A496CDD-3141-455D-9E74-D11FBAEE99E7

P50

Q34447842-730C2AE3-FD78-422C-926B-78E82A7F4F70

Q34447842-9D498A19-6ECD-49F6-9AF9-EF5CF2F0BAC6

P577

Q34447842-51E447FF-3C60-4559-BBB3-4016E65159B9

P5875

Q34447842-82FD664F-488C-40CF-B3F0-9215BB2934C9

P698

Q34447842-7D32CE3D-9F6C-4826-BAEC-E48D258C693F

P921

Q34447842-BFAFEA07-ABF8-45F7-8FF2-846544A882A8

P932

Q34447842-DC88BAB0-1C3B-458F-80ED-515CDB6D67D5

P356

JOURNAL.PONE.0047066

P1433

P1476

Ex vivo effect of varespladib ...... activity in infants with ARDS

@en

P2093

Angelo Minucci

http://www.w3.org/2001/XMLSchema#string

Bruno Giardina

http://www.w3.org/2001/XMLSchema#string

Ettore D Capoluongo

http://www.w3.org/2001/XMLSchema#string

Francesca Vendittelli

http://www.w3.org/2001/XMLSchema#string

Giorgio Conti

http://www.w3.org/2001/XMLSchema#string

Laura Marzano

http://www.w3.org/2001/XMLSchema#string

Leonarda Gentile

http://www.w3.org/2001/XMLSchema#string

Marco Piastra

http://www.w3.org/2001/XMLSchema#string

P2860

Surfactant alteration and replacement in acute respiratory distress syndrome

Structure-based design of the first potent and selective inhibitor of human non-pancreatic secretory phospholipase A2

Bronchopulmonary dysplasia

The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination

Bronchoalveolar lavage in children. ERS Task Force on bronchoalveolar lavage in children. European Respiratory Society.

Secretory phospholipase A₂ pathway during pediatric acute respiratory distress syndrome: a preliminary study.

Effects of varespladib methyl on biomarkers and major cardiovascular events in acute coronary syndrome patients.

Diagnosis and management of bronchiolitis.

Effects of 1-H-indole-3-glyoxamide (A-002) on concentration of secretory phospholipase A2 (PLASMA study): a phase II double-blind, randomised, placebo-controlled trial.

Corticosteroids in the prevention and treatment of acute respiratory distress syndrome (ARDS) in adults: meta-analysis

P304

e47066

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0047066

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P50

Daniele De Luca

P577

2012-10-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

232257346

http://www.w3.org/2001/XMLSchema#string

P698

23071714

http://www.w3.org/2001/XMLSchema#string

P921

acute respiratory distress syndrome

P932

3469496

http://www.w3.org/2001/XMLSchema#string